Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aurinia Pharm Ord (NQ: AUPH )

13.97 USD -0.04 (-0.29%)
Streaming Delayed Price Updated: 1:12 PM EDT, Jun 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,274,712
Open 13.95
Bid (Size) 13.95 (5)
Ask (Size) 13.96 (3)
Prev. Close 14.01
Today's Range 13.62 - 14.00
52wk Range 9.720 - 20.50
Shares Outstanding 128,156,427
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Company’s Board of Directors effective... 
From Business Wire News Releases
Aurinia Announces Results of the 2021 Annual General Meeting
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) is pleased to announce that the eight incumbent directors of the Company were elected at the Company’s annual general... 
From Business Wire News Releases

Performance

YTD
+3.18%
+3.18%
1 Month
+10.43%
+10.43%
3 Month
+8.63%
+8.63%
6 Month
+3.40%
+3.40%
1 Year
-12.80%
-12.80%

More News

Read More
Aurinia Announces Additional Analysis of its AURORA 1 Phase 3 Study Data Presented at ERA-EDTA 2021 Congress
From Business Wire News Releases
Bullish Two Hundred Day Moving Average Cross - AUPH
Tags Stocks
From Market News Video
venBio Raises $550 Million Venture Capital Fund Focused on Life Sciences
From Business Wire News Releases
Interesting AUPH Put And Call Options For August 20th
Tags Stocks
From Market News Video
Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
From Business Wire News Releases
Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis
From Business Wire News Releases
How The Pieces Add Up: BIB Headed For $105
Tags ETFs
From ETF Channel
Unusual Options Activity Insight: Aurinia Pharmaceuticals
Tags BZI/UOA AUPH Benzinga
From Benzinga
Aurinia's Lupkynis Shows Sustained Renal Response Rates In Lupus Nephritis Patients
Tags General Benzinga Health Care
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.